NORTH CHICAGO, Ill. and
CHICAGO, Dec. 5, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV),
a global biopharmaceutical company, and Northwestern University today announced they signed
a five-year collaboration agreement with the goal of advancing
research and discovery in oncology. Together, AbbVie and the Robert
H. Lurie Comprehensive Cancer Center of Northwestern University will work in several areas
of oncology research, which in addition to others could include,
lung, colorectal, breast, prostate and hematological cancer.
"One of the best steps AbbVie can take to deliver new therapies
in oncology is to combine our research and discovery expertise with
the talents and insight of our colleagues in academic medicine,"
said Gary Gordon, M.D., Ph.D., vice
president, oncology clinical development, AbbVie. "The opportunity
to work with leading researchers and clinicians from the Lurie
Cancer Center enhances AbbVie's ability to help oncology patients
even more in the future."
The collaboration provides Lurie Cancer Center scientists with
the opportunity to access new therapies developed by AbbVie for
preclinical research funded under the agreement. Lurie Cancer
Center scientists will also work closely with AbbVie's research
teams to support scientific knowledge exchange. In addition, the
agreement provides AbbVie with the option to obtain an exclusive
license of certain Lurie Cancer Center discoveries made as a result
of the five-year collaboration.
"The ability to investigate new therapeutic agents with AbbVie
provides us with a great opportunity to expand our translational
oncology efforts," said Leonidas C. Platanias, M.D., Ph.D.,
director of the Lurie Cancer Center. "Our partnership with AbbVie
will facilitate and accelerate the development of innovative new
therapies against a wide variety of different cancers."
A joint steering committee comprised of representatives from
both organizations will determine the research projects that the
collaboration will undertake. Researchers from AbbVie and the Lurie
Cancer Center will also hold a symposium at least once each year to
discuss their joint research and potential ideas for new research
projects.
About AbbVie
AbbVie is a global,
research-based biopharmaceutical company formed in 2013 following
separation from Abbott Laboratories. The company's mission is to
use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address
some of the world's most complex and serious diseases. Together
with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs
more than 28,000 people worldwide and markets medicines in more
than 170 countries. For further information on the company and its
people, portfolio and commitments, please visit www.abbvie.com.
Follow @abbvie on Twitter or view careers on our Facebook or
LinkedIn page.
About the Robert H. Lurie Comprehensive Cancer Center of
Northwestern University
Lurie
Cancer Center, one of only 47 National Cancer Institute-designated
Comprehensive Cancer Centers in the country, is committed to being
a national leader in the battle to overcome cancer. To this end,
Lurie Cancer Center is dedicated to scientific discovery, advancing
medical knowledge, providing compassionate, state-of-the-art cancer
care, and training the next generation of clinicians and
scientists. Outstanding basic, translational, and clinical research
complements a full range of prevention, early detection, treatment,
rehabilitation and palliative care programs for all types of
cancer. For information about Lurie Cancer Center's patient care,
programs and services, research and clinical trials, please visit
cancer.northwestern.edu.
Logo - http://photos.prnewswire.com/prnh/20160706/386913LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abbvie-and-northwestern-universitys-lurie-cancer-center-to-collaborate-on-multi-year-cancer-research-agreement-300372461.html
SOURCE AbbVie